The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy

Cardiovascular Research

Volumn 61, Issue 2, 2004, Pages 297-306

  Nikolaidis, Lazaros A ^a   Sturzu, Anthony ^a   Stolarski, Carol ^a   Elahi, Dariush ^b   Shen, You Tang ^c   Shannon, Richard P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt 1; Dilated cardiomyopathy; GLUT 4; Insulin resistance; NEFA; Norepinephrine

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; GLUCOSE; INSULIN; LACTIC ACID; PROTEIN KINASE B; SERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; DOG; FEMALE; GLUCOSE TRANSPORT; HEART; HEART RIGHT VENTRICLE; HEART VENTRICLE PACING; HEMODYNAMICS; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; CYTOSOL; DOGS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; INSULIN; INSULIN RESISTANCE; LACTIC ACID; MALE; MODELS, ANIMAL; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; MYOCARDIUM; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER;

EID: 0347753367     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2003.11.027     Document Type: Article

References (35)

1. Paolisso G., Gambardella A., Galzerano D.et al. Total-body myocardial substrate oxidation in congestive heart failure. Metabolism. 43:1994;174-179.
2. Lommi J., Kupari M., Yki-Jarvinen H. Free fatty acid kinetics and oxidation in heart failure. Am. J. Cardiol. 81:1998;44-55.
3. Feinendegen L.E., Henrich M.M., Kuikka J.T.et al. Myocardial lipid turnover in dilated cardiomyopathy: a dual in vivo tracer approach. J. Nucl. Cardiol. 2:1995;42-52.
4. Taylor M., Wallhaus T.R., Degrado T.R.et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluoro-6-thia-heptadecanoic acid and [18F] FDG in patients with congestive heart failure. J. Nucl. Med. 42(1):2001;55-62.
5. Yazaki Y., Isobe M., Takahashi W.et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart. 81(2):1999;153-159.
6. Wallhaus T.R., Taylor M., DeGrado T.R.et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circles. 103(20):2001;2441-2446.
7. Davila-Roman V.G., Vedala G., Herrero P.et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 40(2):2002;271-277.
8. Osorio J.C., Stanley W.C., Linke A.et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circles. 106(5):2002;606-612.
9. Liao R., Nascimben L., Friedrich J.et al. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ. Res. 78(5):1996;893-902.
10. Razeghi P., Young M.E., Alcorn J.L.et al. Metabolic gene expression in fetal and failing human heart. Circles. 104:2001;2923-2931.
11. Shen W., Asai K., Uechi M.et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs. Circles. 100(20):1999;2113-2118.
12. Shannon R.P., Friedrich S., Mathier M.et al. Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure. Cardiovasc. Res. 34:1997;464-472.
13. Nikolaidis L.A., Hentosz T., Doverspike A.et al. Mechanisms whereby rapid RV pacing causes LV dysfunction: perfusion-contraction matching and NO. Am. J. Physiol, Heart Circ. Physiol. 281:2001;H2270-H2281.
14. 2 utilization in heart failure. Cardiovasc. Res. 53:2002;392-404.
15. Bergmeyer H.U. Methods of enzymatic analysis. 1963;117 Academic Press, New York.
16. Sitsapesan R., Williams A.J. Mechanisms of caffeine activation of single calcium-release channels of sheep cardiac sarcoplasmic reticulum. J. Physiol. 423:1990 (Apr.);425-439.
17. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
18. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc. Natl. Acad. Sci. U. S. A. 76(9):1979;4350-4354.
19. Groop L.C. Insulin resistance: the fundamental trigger to type 2 diabetes. Diabetes Obes. Metab. (Suppl. 1):1999;S1-S7.
20. Coats A.J., Anker S. Insulin resistance in chronic heart failure. J. Cardiovasc. Pharmacol. 35(7 Suppl. 4):2000;S9-S14.
21. Swan J.W., Anker S.D., Walton C.et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 30:1997;527-532.
22. Paolisso G., De Riu S., Marrazzo G.et al. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metab. Clin. Exper. 40(9):1991;972-977.
23. Paolisso G., Tagliamonte M.R., Rizzo M.R.et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am. J. Cardiol. 83(9):1999;1338-1344.
24. Recchia F.A., Osorio J.C., Chandler M.P.et al. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am. J. Physiol: Endocrin. Metab. 282(1):2002;E197-E206.
25. Jagasia D., Whiting J.M., Concato J.et al. Effect of non-insulin- dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circles. 103(13):2001 (Apr. 3);1734-1739.
26. Murakami K., Mizushige K., Noma T.et al. Perindopril effect on uncoupling protein and energy metabolism in failing rat hearts. Hypertension. 40:2002;251-255.
27. Sharov V.G., Todor A.V., Silverman N.et al. Abnormal mitochrondrial respiration in failed human myocardium. J. Mol. Cell Cardiol. 32:2000;2361-2367.
28. Territo P.R., Mootha V.K., French S.A.et al. Ca (2+) activation of heart mitochrondrial oxidative phosphorylation: role of F(0)/F(1)-ATPase. Am. J. Physiol., Cell Physiol. 278:2000;C423-C435.
29. Rocchini A.P., Wilson R.F., Marker P.et al. Metabolic and hemodynamic effects of a graded intracoronary insulin infusion in normal and fat anesthetized dogs: a preliminary study. Hypertension. 27:1996;354-359.
30. Issekutz B., Issekutz T.B., Elahi D.et al. Effect of insulin infusions of the glucose kinetics in alloxan-streptozotocin diabetic dogs. Diabetologia. 10(4):1974;323-328.
31. Jiang G., Zhang B.B. PI 3-kinase and its up- and downstream modulators as potential targets for the treatment of type 2 diabetes mellitus. Front. Biosci. 7:2002;904-917.
32. Kahn B.B., Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106(4):2000;473-481.
33. Saltiel A.R. The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J. Clin. Invest. 106(2):2000 (Jul.);163-164.
34. Hemmings B.A., Brazil D.P. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem. Sci. 26:2001 (Nov.);657-664.
35. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival an insulin response. J. Cell. Sci. 114:2001;2903-2910.